Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1805370 | 1.00 | POLB (0.43) | POLBKDM4EALOX15KMT2AMEN1 | |
| SCHEMBL1805372 | 1.00 | POLB (0.43) | POLBKDM4EALOX15KMT2AMEN1 | |
| SCHEMBL860406 | 0.87 | MAPKAPK2 (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL860405 | 0.87 | MAPKAPK2 (0.41) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL1807470 | 0.87 | MEN1 (0.34) | POLBKDM4EALOX15KMT2AMEN1 | |
| SCHEMBL1807469 | 0.87 | MEN1 (0.34) | POLBKDM4EALOX15KMT2AMEN1 | |
| SCHEMBL860900 | 0.85 | MAPKAPK2 (0.46) | POLBKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL860901 | 0.85 | MAPKAPK2 (0.46) | POLBKDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL861956 | 0.84 | ALDH1A1 (0.43) | POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL861957 | 0.84 | ALDH1A1 (0.43) | POLBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432783-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2013-05-01 | — | — | EP | claimed |
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | disclosed |
| EP-2571353-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2432783-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011146089-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | POLB 4355/4885KDM4E 1480/4885ALOX15 385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.